Newsroom

Each year, landmarks, homes, and communities across the country light up in red to honor those affected by amyloidosis and to raise awareness of this rare disease. Light the Night for Amyloidosis is a simple but powerful way to spark conversation, encourage earlier diagnosis, and show solidarity with patients, caregivers, families, and clinicians who are part of our community.

We...

JAMA Cardiol

Published Online: November 8, 2025

Today at the AHA congress in New Orleans, BridgeBio presented data showing that acoramidis significantly reduces all-cause mortality (through month 42) in people living with hereditary ATTR-CM population, with specific benefit noted in those living with the V122i variant. These data have also been published today in JAMA Cardiology.

You can read more information about this...

Be sure to catch up on the latest happenings in our fall newsletter here!

Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
A three-way tussle has emerged in the growing ATTR amyloidosis market as Alnylam and BridgeBio Pharma have secured FDA approvals to challenge Pfizer.

Tafamidis, which Pfizer sells as Vyndaqel, Vyndamax and Vynmac, had the ATTR...

Below is a resource for our patients:

Taylor & Francis is a publisher of peer-reviewed medical journals. We publish a type of article called Plain Language Summary of Publications (PLSPs). These articles provide an overview of a published, scientific journal article written in non-technical language. These summaries enable a wide audience, including patient audiences, to be able to access and...